Holen Sie sich die Stockscreener-App
2.345
2.70%
-0.065
Handel nachbörslich:
2.34
-0.005
-0.21%
Milestone Pharmaceuticals Inc Aktie (MIST) Neueste Nachrichten
Best Penny Stocks To Watch TodayDecember 15th - MarketBeat
MIST Stock Upgraded to 'Buy' by TD Cowen with New Price Target | - GuruFocus
MIST: Analyst Raises Price Target by 60% Amid Positive Outlook | - GuruFocus
Milestone Pharmaceuticals Poised for Success with Cardamyst Approval and Strong Market Potential - TipRanks
Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval - Investing.com UK
Milestone Pharmaceuticals (NASDAQ:MIST) Raised to Buy at TD Cowen - MarketBeat
Milestone’s long regulatory road ends in approval for Cardamyst - PharmaLive
Milestone Pharmaceuticals Gains FDA Approval for CARDAMYST - TipRanks
Why Is Milestone Pharmaceuticals Stock Skyrocketing Monday?Milestone Pharmaceuticals (NASDAQ:MIST) - Benzinga
Milestone Pharmaceuticals (MIST) Stock: Wild Price Swings Follow FDA Approval Decision - Blockonomi
Milestone Pharmaceuticals shares rally after FDA greenlights first at-home PSVT nasal therapy - MSN
MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns - Stocktwits
Milestone Pharma gains on FDA approval of nasal spray for patients with heart condition - TradingView — Track All Markets
Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025) - ts2.tech
Milestone Pharmaceuticals (NASDAQ:MIST) Strengthens Cardiovascular Research - Kalkine Media
Milestone Pharmaceuticals (MIST) Receives FDA Approval for CARDA - GuruFocus
Milestone Pharmaceuticals Sees Stock Recovery Despite Market Volatility - StocksToTrade
Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025) - ts2.tech
Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by Wall Street Zen to Sell - MarketBeat
Milestone (NASDAQ: MIST) gains FDA approval for self-use CARDAMYST PSVT spray - Stock Titan
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - GlobeNewswire Inc.
Rocket Lab (RKLB) Stock News Today: Neutron “Hungry Hippo” Milestone, Launch Updates, and Analyst Forecasts (Dec. 12, 2025) - ts2.tech
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025) - ts2.tech
Milestone Pharmaceuticals Eyes FDA Approval Amid Strong Q3 Results - timothysykes.com
A new trading data show Milestone Pharmaceuticals Inc (MIST) is showing positive returns. - setenews.com
Is Milestone Pharmaceuticals Inc. stock recession proofDip Buying & Long-Term Growth Stock Strategies - Newser
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Milestone Pharmaceuticals (Nasdaq: MIST) issues 30,000 options at $2.69 under 2021 Inducement Plan - Stock Titan
Stock Traders Purchase Large Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
EV Market: Will Milestone Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Momentum & Advanced Swing Trade Entry Plans - BỘ NỘI VỤ
Milestone Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals Inc (MIST) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Will Milestone Pharmaceuticals Inc. stock gain from lower inflation2025 Volatility Report & AI Enhanced Trading Alerts - BỘ NỘI VỤ
Healthy Upside Potential: Milestone Pharmaceuticals Inc (MIST) - setenews.com
Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects - Insider Monkey
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership - Pasadena Now
Grasim Industries Limited Trading Near Value Zone Recovery AheadRetail Investor Activity & Low Entry Risk Stocks - earlytimes.in
13 Best Canadian Penny Stocks to Buy Right Now - Insider Monkey
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Business Wire
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Milestone Pharmaceuticals Prepares for CARDAMYST Launch Amid Financial Growth - MSN
Milestone Pharmaceuticals Inc. (MIST) stock price, news, quote and history - Yahoo Finance UK
Milestone Pharmaceuticals Inc. (MIST) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Is Milestone Pharmaceuticals Inc. stock bottoming outJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
How analysts rate Milestone Pharmaceuticals Inc. stock today2025 Market Trends & Daily Oversold Bounce Ideas - newser.com
Published on: 2025-11-20 02:01:48 - newser.com
Can Milestone Pharmaceuticals Inc. recover in the next quarter2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
Published on: 2025-11-19 17:33:54 - newser.com
Why analysts remain bullish on Milestone Pharmaceuticals Inc. stockJuly 2025 PreEarnings & Intraday High Probability Setup Alerts - newser.com
Published on: 2025-11-19 13:39:11 - newser.com
It makes sense and dollars to buy Milestone Pharmaceuticals Inc (MIST) stock - Setenews
Published on: 2025-11-19 06:17:41 - newser.com
Using Bollinger Bands to evaluate Milestone Pharmaceuticals Inc.Weekly Volume Report & AI Powered Market Entry Ideas - newser.com
How Milestone Pharmaceuticals Inc. stock reacts to oil pricesTreasury Yields & Daily Market Momentum Tracking - newser.com
0.36%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):